Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...
Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 12.6%, or 30c, after results ...
Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share. Rani Therapeutics Holdings Inc ...
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) provided a look at new preclinical data for a glucagon-like peptide-1 (GLP-1) incretin triagonist. In addition to a discussion to this data ...
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants Rani Therapeutics, LLC Tue, Oct 15, 2024, 8:30 AM 3 min ...
Shares of NASDAQ:RANI opened at $2.68 on Friday. Rani Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.75. The company’s 50-day moving average price is $2.57 and its two ...
Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company ...
On Thursday, H.C. Wainwright maintained a positive outlook on Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), reiterating a Buy rating and a price target of $9.00. The firm's endorsement follows Rani ...
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback